House Committee Blocks Cannabis Rescheduling Despite Trump Support
Congressional appropriators vote to halt federal marijuana reform progress, creating political clash with administration's pro-rescheduling stance.
The House Appropriations Committee delivered a direct challenge to federal cannabis reform Wednesday, approving funding language that blocks further rescheduling efforts despite the Trump administration's commitment to advance the policy change. The provision creates an unusual political dynamic where congressional Republicans oppose their own party's executive branch on a key industry issue that could unlock billions in market value.
The committee's action injects fresh uncertainty into cannabis markets at a critical juncture. Major operators like Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF) have built business models around eventual federal reform, with rescheduling representing the most immediate path to reduced tax burdens and expanded banking access. The legislative roadblock threatens to extend the timeline for these fundamental changes, potentially impacting valuations across the sector.
Cannabis companies currently face effective tax rates exceeding 70% due to Internal Revenue Code Section 280E, which prohibits standard business deductions for federally illegal substances. Rescheduling marijuana from Schedule I to Schedule III would eliminate this tax penalty, potentially adding hundreds of millions in annual cash flow to major operators. The appropriations language directly targets this reform pathway, creating a legislative firewall against regulatory progress.
The political split reveals deeper tensions within Republican ranks over cannabis policy. While the Trump administration signals support for industry-friendly reforms, traditional law enforcement allies in Congress maintain opposition to any liberalization measures. This divide complicates the legislative landscape for broader reforms like the SAFE Banking Act, which has stalled despite bipartisan support and industry lobbying.
Market participants now face a more complex regulatory timeline, with congressional appropriations potentially overriding administrative rescheduling efforts. The funding bill requires full House and Senate approval, setting up a broader political battle over federal cannabis policy. Investors must weigh the administration's reform commitment against congressional resistance, adding another layer of political risk to an already complex regulatory environment.